OR WAIT null SECS
Cosentyx is the first intravenous formulation interleukin-17A antagonist to focus on disease.
Novartis officially announced that the FDA approved n intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Currently, Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-α) IV option available in all these indications.
"At Novartis, we are committed to ensuring healthcare providers and patients have treatment options available to meet their unique needs. With this approval of Cosentyx as an IV formulation, along with the subcutaneous formulation, we can broaden the use of Cosentyx to help more patients manage their condition with a medicine backed by more than a decade of clinical research and eight years of real-world experience," said Christy Siegel, VP, head of immunology, Novartis US.
Reference: FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases. PR Newswire. October 6, 2023. Accessed October 9, 2023. https://www.prnewswire.com/news-releases/fda-approves-novartis-cosentyx-as-first-intravenous-iv-formulation-interleukin-17a-antagonist-for-rheumatic-diseases-301949928.html